Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders
Peripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/5/607 |
| _version_ | 1797496844562989056 |
|---|---|
| author | Jeremy Chung Bo Chiang Ria Arnold Roshan Dhanapalaratnam Maria Markoulli Arun V. Krishnan |
| author_facet | Jeremy Chung Bo Chiang Ria Arnold Roshan Dhanapalaratnam Maria Markoulli Arun V. Krishnan |
| author_sort | Jeremy Chung Bo Chiang |
| collection | DOAJ |
| description | Peripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation in advanced cases. Recent studies have indicated a high prevalence of neuropathy in patients with chronic kidney disease, also known as uraemic neuropathy. Immune-mediated neuropathies including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy may cause significant physical disability. As survival rates continue to improve in cancer, the prevalence of treatment complications, such as chemotherapy-induced peripheral neuropathy, has also increased in treated patients and survivors. Notably, peripheral neuropathy associated with these conditions may be chronic and long-lasting, drastically affecting the quality of life of affected individuals, and leading to a large socioeconomic burden. This review article explores some of the major emerging clinical and experimental therapeutic agents that have been investigated for the treatment of peripheral neuropathy due to metabolic, toxic and immune aetiologies. |
| first_indexed | 2024-03-10T03:09:20Z |
| format | Article |
| id | doaj.art-47409c803d3d4ccdba976c38463ef849 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T03:09:20Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-47409c803d3d4ccdba976c38463ef8492023-11-23T12:35:18ZengMDPI AGPharmaceuticals1424-82472022-05-0115560710.3390/ph15050607Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve DisordersJeremy Chung Bo Chiang0Ria Arnold1Roshan Dhanapalaratnam2Maria Markoulli3Arun V. Krishnan4School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney 2052, AustraliaSchool of Medical, Indigenous and Health Science, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong 2500, AustraliaPrince of Wales Clinical School, University of New South Wales, Sydney 2052, AustraliaSchool of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney 2052, AustraliaPrince of Wales Clinical School, University of New South Wales, Sydney 2052, AustraliaPeripheral nerve disorders are caused by a range of different aetiologies. The range of causes include metabolic conditions such as diabetes, obesity and chronic kidney disease. Diabetic neuropathy may be associated with severe weakness and the loss of sensation, leading to gangrene and amputation in advanced cases. Recent studies have indicated a high prevalence of neuropathy in patients with chronic kidney disease, also known as uraemic neuropathy. Immune-mediated neuropathies including Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy may cause significant physical disability. As survival rates continue to improve in cancer, the prevalence of treatment complications, such as chemotherapy-induced peripheral neuropathy, has also increased in treated patients and survivors. Notably, peripheral neuropathy associated with these conditions may be chronic and long-lasting, drastically affecting the quality of life of affected individuals, and leading to a large socioeconomic burden. This review article explores some of the major emerging clinical and experimental therapeutic agents that have been investigated for the treatment of peripheral neuropathy due to metabolic, toxic and immune aetiologies.https://www.mdpi.com/1424-8247/15/5/607cancerchemotherapychronic kidney failurediabetes mellitusimmune system diseasesneuropathy |
| spellingShingle | Jeremy Chung Bo Chiang Ria Arnold Roshan Dhanapalaratnam Maria Markoulli Arun V. Krishnan Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders Pharmaceuticals cancer chemotherapy chronic kidney failure diabetes mellitus immune system diseases neuropathy |
| title | Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders |
| title_full | Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders |
| title_fullStr | Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders |
| title_full_unstemmed | Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders |
| title_short | Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders |
| title_sort | current and emerging pharmacotherapeutic interventions for the treatment of peripheral nerve disorders |
| topic | cancer chemotherapy chronic kidney failure diabetes mellitus immune system diseases neuropathy |
| url | https://www.mdpi.com/1424-8247/15/5/607 |
| work_keys_str_mv | AT jeremychungbochiang currentandemergingpharmacotherapeuticinterventionsforthetreatmentofperipheralnervedisorders AT riaarnold currentandemergingpharmacotherapeuticinterventionsforthetreatmentofperipheralnervedisorders AT roshandhanapalaratnam currentandemergingpharmacotherapeuticinterventionsforthetreatmentofperipheralnervedisorders AT mariamarkoulli currentandemergingpharmacotherapeuticinterventionsforthetreatmentofperipheralnervedisorders AT arunvkrishnan currentandemergingpharmacotherapeuticinterventionsforthetreatmentofperipheralnervedisorders |